Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model

Gail Torkildsen,1 Abhijit Narvekar,2 Mark Bergmann3 1Andover Eye Associates, Andover, MA, 2Alcon Research Ltd, Fort Worth, TX, 3Apex Eye, Cincinnati, OH, USA Background: Symptom relief for the duration of 24 hours after treatment would benefit patients with allergic conjunctivitis. Objective: To co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Torkildsen G, Narvekar A, Bergmann M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/7cd5332632fa45a4bb648507e0466e30
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!